Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
21.26
-0.86 (-3.89%)
At close: Apr 28, 2026, 4:00 PM EDT
21.55
+0.29 (1.36%)
Pre-market: Apr 29, 2026, 7:39 AM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
16.50B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Exelixis | 2.32B |
| Moderna | 1.94B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
SMMT News
- 20 days ago - Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Benzinga
- 4 weeks ago - Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
- 6 weeks ago - Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 2 months ago - Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Summit Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Business Wire
- 2 months ago - Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - Business Wire